Provided by Tiger Trade Technology Pte. Ltd.

CLOVER BIO-B

2.280
+0.0602.70%
Volume:2.25M
Turnover:5.14M
Market Cap:2.96B
PE:-2.80
High:2.330
Open:2.290
Low:2.260
Close:2.220
52wk High:3.180
52wk Low:0.185
Shares:1.30B
HK Float Shares:1.30B
Volume Ratio:0.83
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.814
ROE:-648.53%
ROA:-47.64%
PB:-1.53
PE(LYR):-2.80
PS:50.58

Loading ...

Clover Biopharmaceuticals (02197) Announces January 2026 Monthly Return Updates

Bulletin Express
·
Feb 04

Zaozhuang Mobile Innovatively Builds "Clover" Ideological and Political Work Model

Deep News
·
Jan 27

CLOVER BIO-B (02197) Initiates Phase 2 Clinical Trial for RSV-hMPV-PIV3 Respiratory Combination Vaccine Candidate

Stock News
·
Jan 12

Clover Initiates Phase 2 Clinical Trial for Rsv + Hmpv ± Piv3 Respiratory Combination Vaccine Candidates

THOMSON REUTERS
·
Jan 12

Clover Biopharmaceuticals Launches Phase 2 Trial for RSV-hMPV-PIV3 Combination Vaccine Candidates

Reuters
·
Jan 12

Clover Biopharmaceuticals, Ltd.'s (HKG:2197) market cap rose HK$311m last week; retail investors who hold 53% profited and so did insiders

Simply Wall St.
·
Jan 07

10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled

Stock News
·
Dec 03, 2025

Clover Biopharmaceuticals (02197) Announces Monthly Return for October 2025

Bulletin Express
·
Nov 05, 2025

Wang Xiaodong: 15th National Games to Help Guangzhou Become a City of Sports for All

Deep News
·
Oct 28, 2025

Clover Biopharmaceuticals Appoints Nicholas Jackson as President of Global R&D and Alliances

Reuters
·
Oct 20, 2025

Peng Liang Spends CN¥545k On Clover Biopharmaceuticals Stock

Simply Wall St.
·
Oct 18, 2025

Hong Kong Stock Alert | CLOVER BIO-B (02197) Opens Up Over 5% on Positive Preliminary Clinical Trial Data

Stock News
·
Oct 15, 2025

Clover Biopharmaceuticals Ltd - Increases in Neutralizing Antibodies Observed for Rsv, Hmpv, Piv3

THOMSON REUTERS
·
Oct 14, 2025

Clover Announces Positive Phase I Clinical Data for Rsv-Hmpv-Piv3 Combination Vaccines and for Rsv Re-Vaccination in Older Adults

THOMSON REUTERS
·
Oct 14, 2025

Clover Biopharmaceuticals Ltd - Rsv+Hmpv±Piv3 Vaccine Candidates to Advance to Phase Ii Trials in First Half of 2026

THOMSON REUTERS
·
Oct 14, 2025

CLOVER BIO-B (02197) Announces Positive Phase I Clinical Trial Data for Respiratory Combination Vaccine (RSV-hMPV-PIV3) and RSV Vaccine Booster in Elderly Population

Stock News
·
Oct 14, 2025

Clover Biopharmaceuticals Announces Positive Phase I Data for RSV-HMPV-PIV3 Combination Vaccines, Plans Phase II Trials in 2026

Reuters
·
Oct 14, 2025

Hong Kong Stock Alert | CLOVER BIO-B (02197) Surges Over 21% Following Announcement of Phase I Clinical Trial Launch for Respiratory Combination Vaccine Candidates

Stock News
·
Oct 02, 2025

HK Movers | Biotech Stocks Jump With Biocytogen up 11%

Tiger Newspress
·
Sep 18, 2025

Biotech Stocks Rebound. Transthera up 16%; Hightide up 13%; Clover Bio up over 9%; Alphamab up 8%; Zai Lab, Jacobio up over 6%; Mirxes up 5%

Tiger Newspress
·
Sep 12, 2025